SGMOQ
Sangamo Therapeutics, Inc
$0.07
0.00 (-5.41%)
At close · Jul 2
Market Cap
$30.66M
Shares
414,288,847
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.07
Open$0.06
Day$0.05–0.08
52W$0.05–0.77
Avg vol 30d4.0M
Short int24.8M · 6.0% float · 4.1d
Short vol39%
Last earningsMay 14, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 14
Equibles Rating
blended score · not investment advice
Overall
Neutral
Technical · trend & momentum
Strong Sell
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−82% below
−
Price vs 50-day avg
−55% below
◦
RSI (14)
28 · oversold
−
MACD trend
negative
−
52-week position
3% · near low
Sentiment · smart money
Bearish
◦
Trend (MA cross)
50d $0 › 200d $0 — 200d above 50d
+
Institutional flow
+8% holders QoQ · +29 funds added
−
Insider flow
Net -$106.9K over 90 days · 100% sells
−
Short interest
5.98% of float · ▲ +0.8% MoM · 4.1 days cover
◦
Volume signal
High volume on a down day — possible exhaustion
◦
Institution breadth
114 holders — mid 3-yr range
Fundamentals
Strong
+
Revenue growth
+89% Y/Y
+
EPS growth
+10% Y/Y
−
Free cash flow
$-97.3M
+
Balance sheet
net cash $20.9M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Sep 8, 2026
Est · unconfirmed
· in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−82% below
Bearish
Price vs 50-day avg
−55% below
Bearish
RSI (14)
28 · oversold
Neutral
MACD trend
negative
Bearish
52-week position
3% · near low
Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Accumulating
+8% holders QoQ · +29 funds added
Insider flow
Distributing
Net -$106.9K over 90 days · 100% sells
Short interest
Rising
5.98% of float · ▲ +0.8% MoM · 4.1 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
114 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $0
Now $0 · 3%
52-wk high $1
vs 200-day avg -82%
vs 50-day avg -55%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP operating expenses non-GAAP | $31.7M | Three Months Ended March 31, 2026 | -76.4% |
|
|
|||
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SGMOQ
this stock
Sangamo Therapeutics, Inc
|
$30.66M | -83.3% | +88.6% | — | 6.0% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SGMOQ | -5.4% | -68.2% | -84.4% | -5.4% | -83.3% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | -6.8% | -66.9% | -92.5% | -5.1% | -92.6% |